The global animal model market revenue was around US$ 1.9 billion in 2022 and is estimated to reach US$ 3.3 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.6% during the forecast period from 2023 to 2031.
Animal models are non-human organisms, usually animals, that are used in scientific research to learn more about human health and physiology, explore disease mechanisms, analyze biological processes, and discover new treatments. Animal models play an important role in several fields such as pharmacology, medicine, toxicology, and genetics. They offer researchers a method to understand complicated test hypotheses, and biological systems, and make predictions before moving on to human studies.
Market Driving Factors
The surge in the adoption of clustered regularly interspaced short palindromic repeats (CRISPR) technology drives the market growth. CRISPR is an easy-to-perform, time-saving technique as it enables rapid, cost-effective animal model creation. It enables the development of mutant mouse models that were previously impossible to make using traditional methods. This method has resulted in the creation of knock-out and knock-in animal models for drug testing.
Growth opportunities in emerging markets are expected to boost the market. This is due to the expanding territories, unexplored, enhanced healthcare infrastructure, and increasing medical device and pharmaceutical sectors. In addition, increasing demand for cutting-edge manufacturing technologies and government spending to modernize healthcare facilities are promoting the healthcare industry in emerging nations.
The availability of substitute testing techniques hampers the market growth.
Regional Analysis
North America dominated the market and is estimated to continue its dominance over the forecast period. This can be attributed to the surge in research and development activities by biotech and pharma companies and the strong existence of key market players to offer animal models to meet the demand in the region.
Asia Pacific dominates the market during the forecast period. The high disease burden of chronic disorders, such as immunological disorders, cancer, and rare genetic disorders, is projected to aid the market expansion. Furthermore, substantial investments made by essential industry participants in the region, coupled with supporting government legislation for research, are another element boosting the regional expansion.
Segmentation Insights
Animal Type Insight
The mice segment dominated the market and is expected to witness the fastest growth rate over the forecast period. Factors, such as surge in investments and technological progress in mouse model technology are predicted to propel segment growth. Additionally, increasing implications of mouse clinical trials for more predictive results, and a surge in demand for personalized medicine are further contributing to boosting the segment.
The rat segment is estimated to dominate the market. This is due to the significant genetic similarities between humans and rats, making them appropriate for studying different anatomical, physiological, and behavioural aspects.
End User Insight
The pharma and biotech companies segment dominate the market. The rise in efforts by companies to create novel treatment regimens is estimated to fuel the segment expansion. In addition, growth in development activities & drug discovery by pharmaceutical companies is further contributing to segment growth. Thus, large numbers of research-driven pharmaceutical companies and several initiatives undertaken by them are projected to drive the segment expansion.
Prominent Companies
Segmentation Outline
The global animal model market segmentation focuses on Animal Type, Application, End User, and Region.
By Animal Type
By Application
By End User
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL ANIMAL MODEL MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: ANIMAL MODEL MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL ANIMAL MODEL MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL ANIMAL MODEL MARKET, BY ANIMAL TYPE
5.1 OVERVIEW
5.2 RAT
5.3 MICE
5.4 GUINEA PIGS
5.5 RABBITS
5.6 OTHERS
6 GLOBAL ANIMAL MODEL MARKET, BY APPLICATION
6.1 OVERVIEW
6.2 DRUG DISCOVERY AND DEVELOPMENT
6.3 BASIC RESEARCH
6.4 OTHERS
7 GLOBAL ANIMAL MODEL MARKET, BY END USER
7.1 OVERVIEW
7.2 PHARMA AND BIOTECH COMPANIES
7.3 ACADEMIC RESEARCH INSTITUTES
7.4 OTHERS
8 GLOBAL ANIMAL MODEL MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL ANIMAL MODEL MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 GENOWAY S.A.
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 TRANS GENIC INC
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 THE JACKSON LABORATORY
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 TACONIC BIOSCIENCES
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 CHARLES RIVER LABORATORIES
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 INOTIV INC
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 CROWN BIOSCIENCE INC
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 HERA BIOLABS
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 JANVIER LABS LLC
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 OZGENE PTY LTD
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved